Jad Chahoud, Genitourinary Medical Oncologist at Moffitt Cancer Center, shared a recent article by Rainer Fietkau and colleagues on X:
“CONKO-007 (JCO): Post-induction chemo vs CRT in unresectable PDAC, CRT didn’t improve R0 rate nor OS. Among surgical patients, R0 was higher with CRT (69% vs 50%). Margin gains ≠ survival—where does CRT fit?”
Title: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
Authors: Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A. Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S. Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt, Stefan Boeck, Nicolas Moosmann, Anke C. Reinacher-Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Dorota Lubgan, Annett Kallies, Markus Hecht, Iris Tischoff, Andrea Tannapfel, Benjamin Frey, Helmut Oettle
More posts featuring Jad Chahoud on OncoDaily.